6 Matching Annotations
  1. Aug 2025
  2. www.biorxiv.org www.biorxiv.org
    Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    biorxiv.org/content/10.1101/2025.08.10.669554v1
  3. Apr 2025
  4. www.sciencedirect.com www.sciencedirect.com
    CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2451945625000960
  5. Jun 2024
  6. www.cell.com www.cell.com
    CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    cell.com/iscience/abstract/S2589-0042(24)01200-8
  7. Mar 2024
  8. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10905675/
  9. Feb 2024
  10. 52.53.155.43 52.53.155.43
    cd-23-0954-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/aaf525c30ae01b53e260240fad732783dfb4bbac/cd-23-0954-html.html
  11. Sep 2021
  12. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC8484689/